Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2021-03-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于公司2021年股票期权与限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading and stock transactions by insiders and incentive plan participants related to a 2021 stock option and restricted stock incentive plan. It includes details of stock transactions by insiders during a specified period and concludes no insider trading occurred. The document is an announcement related to compliance and insider trading checks, not a financial report, earnings release, or management report. It does not contain financial statements or detailed financial analysis. It is a regulatory announcement about insider trading compliance and stock transactions by insiders, fitting best under Regulatory Filings (RNS). The document length is short (2029 characters), and it is a formal disclosure rather than a report or presentation.
2021-03-19 Chinese
哈药集团股份有限公司2021年第三次临时股东大会法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2021 third extraordinary general meeting (临时股东大会) of Harbin Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting process and voting outcomes. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, specifically a legal opinion on the shareholder meeting's conduct and results. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2021-03-19 Chinese
哈药集团股份有限公司监事会关于公司2021年股票期权与限制性股票激励计划首次授予部分激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is an official announcement from the supervisory board of Harbin Pharmaceutical Group Co., Ltd. regarding the verification and public disclosure of the initial grant of stock options and restricted stock incentive plan for 2021. It includes details about the public notice, verification process, and confirmation that the incentive recipients meet legal and regulatory requirements. The document is a formal announcement related to the company's stock incentive plan and the supervisory board's opinion on the matter. It does not contain financial statements, earnings data, or detailed management discussion. It is not a full report but an announcement of verification and public disclosure related to a stock incentive plan. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2021-03-12 Chinese
哈药集团股份有限公司2021年第三次临时股东大会会议材料
AGM Information Classification · 100% confidence The document is titled as materials for the 2021 third extraordinary shareholders' meeting of Harbin Pharmaceutical Group Co., Ltd. It includes meeting agenda, voting procedures, and detailed proposals for shareholder approval such as stock option and restricted stock incentive plans, authorization for the board to handle related matters, and a proposal for applying for a working capital loan. The content is clearly related to the materials shared for a shareholders' meeting, including agenda and proposals to be voted on. There is no financial statement or report analysis, nor is it a transcript or announcement of voting results. The document fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting.
2021-03-09 Chinese
哈药集团股份有限公司关于政府征收部分房屋资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 哈药集团股份有限公司 regarding the government's expropriation of certain house assets owned by a subsidiary. It details the compensation amount, the impact on the company's profit and loss, and confirms that the transaction does not constitute a major asset restructuring or related party transaction. The document is relatively short (1275 characters) and serves as a formal notification to shareholders and the market about this specific asset expropriation event and its financial implications. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the transaction and its expected impact. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-03-03 Chinese
哈药集团股份有限公司关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a public announcement by an independent director soliciting proxy voting rights for a specific upcoming shareholders' meeting scheduled on March 19, 2021. It details the voting rights collection process, the agenda items related to a stock option and restricted stock incentive plan, and the procedures for shareholders to authorize the independent director to vote on their behalf. The document does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement related to proxy solicitation for voting at a shareholders' meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, and it is not merely announcing a report publication but actively soliciting votes, confirming it is not a Report Publication Announcement (RPA).
2021-03-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.